Drugs / Nivolumab
Drug research

Nivolumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as BMS-936558; OPDIVO; Opdivo; Opdivo®

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673ExelixisPhase 3Active not recruiting2026-12-15Estimated
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219ExelixisPhase 3Active not recruiting2022-01-31Actual
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332IDEAYA BiosciencesPhase 2, Phase 3Active not recruiting2027-01-15Estimated
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Replimune, Inc.Phase 3Recruiting2030-09-30Estimated
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314Immunocore LtdPhase 3Recruiting2027-10-16Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574ExelixisPhase 3Enrolling by invitation2030-05-31Estimated
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095RCUSPhase 3Completed2026-08-28Actual
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaNCT06581406Replimune, Inc.Phase 2, Phase 3Recruiting2030-01Estimated

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.